We are happy to announce that Hubro Bioscience and Fürst Medisinsk Laboratorium now have signed a letter of intent regarding collaboration on the next phase of the development of Hubro’s diagnostic tools for the specific detection of MSI-cancer related biomarkers in liquid biopsies.
Fürst, with their extensive experience and competence within the field of diagnostics, will secure professional advancement of Hubro’s technology towards commercialization.
The collaboration entails optimization of test-assays, production of prototype kits and conducting a pilot study for initial clinical validation.